Biology of acute renal failure: Therapeutic implications  by Lieberthal, Wilfred
Kidney International, Vol. 52 (1997), pp. 1102-1115
NEPHROLOGY FORUM
Biology of acute renal failure: Therapeutic implications
Principal discussant: WILFRED LIEBERTHAL
Boston Medical Center, Boston, Massachusetts, USA
CASE PRESENTATIONS
Patient I. A 46-year-old black man was brought to the Boston Medical
Center emergency room after being stabbed multiple times in the abdo-
men. Physical examination on arrival revealed a systolic blood pressure of
60mm Hg and a pulse rate of 160 beats/mm. Three deep stab wounds were
present in the abdomen. There was diffuse abdominal tenderness and
guarding. An upright abdominal radiograph revealed free air under the
diaphragm. A Foley catheter was passed and 100 ml of urine was collected.
The urinalysis was normal. Blood urea nitrogen on admission was 15 mg/dl
and serum creatinine was 0.8 mgldl.
The patient received two liters of normal saline intravenously over 30
minutes and then five units of packed red cells over the next three hours.
His blood pressure steadily increased and was 110/60 mm Hg five hours
after admission to the emergency room. He passed no urine for the first
few hours after admission but then began to pass 10 to 15 ml of urine per
hour.
When he was hemodynamically stable, a laparotomy was performed.
Three lacerations of the small bowel were repaired and the spleen
removed because of a severe splenic laceration. He received additional
saline and three more units of blood during surgery. His blood pressure
during surgery was stable at about 115/70 mm Hg. He continued to pass
about 10 to 15 ml of urine during surgery.
The first day after surgery, the patient had a blood pressure of 120/80
mm Hg and a pulse rate of 70 heats/mm. His blood urea nitrogen was 40
mg/dl and his serum creatinine was 1.6 mg/dl. The liver enzymes and
serum amylase were normal. His urine output over the previous 12 hours
had been 200 ml. Urinalysis revealed no blood or protein. 1he sediment
contained many renal tubular epithelial cells and darkly pigmented
('muddy brown") casts. He was given furosemide (160 mg intravenously)
with no response in his urine output. Three hours later, another dose of
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furosemide (320 mg intravenously) again produced no response in the
urine output. No more diuretics were administered.
By the sixth day after surgery, the patient was drowsy and less alert than
usual. Physical examination disclosed asterixis. His respirations were
24/mm; his jugular veins were distended to 6 cm; and chest examination
revealed bibasilar crackles. His cardiac examination was normal. Periph-
eral edema was present. His weight had increased 7 kg since admission. A
chest radiograph showed evidence of mild congestive heart failure. His
blood urea nitrogen had risen to 140 mg/dl and his serum creatinine to 6.5
mg/dl. The serum electrolytes were: sodium, 130 mEq/liter; potassium, 6.2
mEq/liter; chloride, 95 mEq/liter; and bicarbonate, 15 mEq/liter. His urine
output during the previous five days had been approximately 300 cc/day. A
subclavian catheter was placed and hemodialysis begun.
During the next 14 days, he received seven hemodialysis treatments. His
blood urea nitrogen and serum creatinine fell 15 mg/dl and 0.5 mg/dl
respectively during a 24-hour period between the last two hemodialysis
treatments. Hemodialysis was discontinued. Over the next few days, the
blood urea nitrogen fell to 25 mg/dl and the serum creatinine to 1.0 mg/dl,
and the patient was discharged from the hospital.
Patient 2. A 36-year-old man with a 20-year history of insulin-dependent
diabetes mellitus presented to Boston Medical Center with worsening
angina. The patient had a history of coronary artery disease presenting
initially as an uncomplicated myocardial infarction three years before this
admission. He also had severe peripheral vascular disease necessitating a
right aorto-femoral bypass procedure four years previously. In addition, he
had a history of severe diabetic retinopathy and chronic renal dysfunction
(baseline serum creatinine of 3.0 mg/dl) and nephrotic-range proteinuria
presumed to be secondary to diabetic glomerulosclerosis.
After the myocardial infarction, the patient had been asymptomatic and
without chest pain. However, one week before admission he began to
complain of severe central chest pressure whenever he exerted himself,
and which became progressively more severe, frequent, and prolonged
during the course of the week before admission. Physical examination
revealed a blood pressure of 160/93 mm Hg, a pulse rate of 78 heats/mm
(regular), and 18 respirations per minute. No jugular venous distention or
chest or cardiac abnormalities were evident. Abdominal examination was
normal. The patient had bruits over the left carotid and left femoral
arteries. No pedal pulses were palpable bilaterally.
Laboratory data on admission included a blood urea nitrogen of 45
mg/dl and serum creatinine of 3.3 mgldl. Total blood count and serum
electrolytes were normal. The electrocardiogram disclosed evidence of an
old inferior myocardial infarction but no other changes or abnormalities.
Urinalysis revealed 4+ albumin and 2+ glucose, with 2 to 3 red cells/high-
power field and many oval fat bodies in the urinary sediment.
A coronary angiogram was scheduled. The patient received one liter of
0.45% saline prior to the procedure. The intravenous infusion of 0.45%
saline was continued during and after the angiogram at a rate of 120
nil/hour. During the angiogram, the patient received 155 ml of a nonionic
contrast medium. A critical stenosis of the left anterior descending
coronary artery was identified; a successful angioplasty was performed
without complications. The patient received no diuretics before or after
the angiogram.
In the first 24 hours after angiography, he excreted only 200 ml of urine,
and the intravenous infusion was discontinued when the patient developed
hihasilar crackles. At that point, he was given 320 mg of furosenude. A
diuresis of 150 ml ensued over the next three hours. The patient's urine
output then fell again to approximately 15 mI/hour. On the second and
third day after angiography, his serum creatinine rose to 4.6 mg/dl and 5.8
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mg/dl, respectively. The urine sediment, which was examined 071 multiple
occasions, showed oval fat bodies and 5 to 10 renal tubular epithelial
cells/high-power field but no casts.
On the third day post angiography, the urine output increased to 750 ml.
On the fourth day following angiography, the serum creatinine fell to 4.6
mg/dl. Over the next three days, the urine output increased steadily to
approximately 2 liters/day, and the serum creatinine fell to baseline (3.5
mg/dl) before the patient was discharged.
DISCUSSION
DR. WILFRED LIEBERTIIA!. (Renal Section, Boston Medical Cen-
ter, and Associate Professor of Medicine, Boston University School of
Medicine, Boston, Massachusetts, USA): These two cases are
examples of acute renal failure resulting from an ischemic insult
(Patient 1) and radiocontrast-medium-induced renal injury (Pa-
tient 2). This Nephrology Forum will provide an overview of the
recent advances in our understanding of the pathophysiology of
acute renal failure (ARF) that results from acute ischemic or
nephrotoxic insults to the kidney. I will demonstrate how basic
research in this area has led to the potential for the development
of an array of novel forms of treatment for humans with ARF.
Pathophysiology
The term conventionally used in clinical practice to refer to
ARF that results from ischemic or toxic injury to the kidney is
acute tubular necrosis (ATN) [1]. This term accurately defines the
population of cells that are the major target of injury in this form
of ARF. A number of studies, predominantly using micropuncture
techniques and published more than 15 years ago, showed that
renal tubular epithelial cell injury compromises glomerular filtra-
tion rate (GFR) by obstructing tubules and allowing "backleak" of
glomerular filtrate [1—4]. The term "backleak" refers to the
unregulated passage of solute and water from the tubular lumen
into the interstitium and ultimately back into renal venous capil-
laries and renal veins. Subsequent studies by Myers and col-
leagues have provided evidence that both intratuhular obstruction
as well as tubular backleak are important factors leading to the
reduction in GFR associated with ischemic renal failure in
humans [5]. In most cases of ATN, obstruction is due to the
formation of intratubular casts of proteinaceous material that
often contain renal tubular epithelial cells.
Numerous experimental studies of ischemic and toxic ARF in
vivo have consistently demonstrated that the straight portion of
the proximal tubule (the S3 segment) is the most susceptible to
ischemic and toxic injury [6, 71. The cells in this part of the
nephron lose the normal tubular brush border and undergo
extensive cell necrosis. Proximal tubular cells in the cortex (SI and
S2 segments) are less severely damaged; they mainly lose brush
border and show less necrosis than do cells in the straight S3
segment [61. The degree to which cells of the medullary thick
ascending limb (mTAL) segment sustain injury and necrosis
varies in different studies and experimental models, but in general
is far less severe than that suffered by the straight segment of the
proximal tubule [6, 7]. Tubular cells in the inner medulla and
those lining the collecting duct appear to sustain the least injury
i,6].
Despite the results of these studies from the late '70s and early
'80s, controversy has arisen over the last decade regarding the
issue of which segments of the nephron are most severely injured
in ARF. In the early 1980s, Epstein's group hypothesized that the
mTAL segment is the major site of injury in ATN [8]. This theory
was based on work in the isolated kidney perfused by a red-cell-
free perfusate which, without being subjected to any injurious
insult, rapidly develops spontaneous necrosis of cells of the mTAL
with relative sparing of all other nephron segments. This same
morphologic pattern of injury has been consistently reported by
many other groups using the same red-cell-free, isolated perfused
kidney model [9, 10]. But the relevance of this model to the in-vivo
situation was subsequently questioned by studies in isolated
kidneys perfused in the presence of red cells. These investigations
have clearly demonstrated that the extensive necrosis of the
mTAL segment that occurs spontaneously in the isolated perfused
kidney is related to, and depends on, the absence of red cells in
the perfusate. When uninjured isolated kidneys are perfused in
the presence of red cells, all nephron segments, including the
mTAL segment, remain morphologically intact [9, 101. Further-
more, when the isolated erythrocyte-perfused kidney is subjected
to hypoxic [10] or ischemic injury [11—13], the pattern of injury is
indistinguishable from that following ischemia in experimental
models in vivo, with the most severe injury affecting the straight
segment of the proximal tubule. Recent studies demonstrating
that the straight segment of the proximal tubule is the site of
maximal mitotic activity after injury also suggest that lethal injury
is most prominent in this segment [14]. Thus, available evidence
indicates that the cells of the S3 segment of the proximal tubule
sustain the most severe injury following an ischemic or a toxic
renal insult.
Hemodynamic abnormalities: The role of persistent medullary
hypoxia in ATN
A reduction in total renal blood flow to 40% to 50% of normal
has been consistently reported both in experimental animal
models of ARF as well as during the maintenance phase of ATN
in humans [11. For many years, the importance of these hemody-
namic changes in mediating the maintenance phase remained
uncertain. Many investigators concluded that the hemodynamic
alterations were relatively unimportant, because the observed
reduction in renal blood flow is insufficient to account for the
profound reduction in GFR. Furthermore, augmentation of total
renal flow by volume expansion or administration of vasodilators
such as dopamine and prostaglandin analogues does not substan-
tially improve GFR [1]. However, it has become clear that
hemodynamic abnormalities do play an important role in ATN by
causing persistent regional disturbances in renal blood flow and
oxygen supply that predominantly affect the outer medulla of the
kidney [15—17].
The medulla of the normally perftised kidney is constantly in a
markedly hypoxic state (P02 of 10—20 mm Hg), whereas the
oxygen tension of the cortex is about 50 mm Hg [15, 18]. The
hypoxic state of the normal medulla is due to countercurrent
diffusion of oxygen from descending (arterial) to ascending (ve-
nous) vasa rectae and is therefore a necessary consequence of the
concentrating mechanism of the kidney [15, 18]. Oxygen utiliza-
tion that is needed for active solute transport by the straight
proximal tubule segments and mTAL segments also contributes to
the low oxygen tensions in this region of the kidney [15]. Follow-
ing an ischemic or toxic insult to the kidney, oxygen tension in the
medulla falls even further because of a persistent reduction in
blood flow [15, 16]. Thus, the hemodynamic abnormalities asso-
ciated with ARF likely contribute to renal dysfunction by main-
taining the tubular segments within the outer medulla in a
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persistent state of severe hypoxia, thereby adding to, as well as
prolonging, the initial ischemic or toxic insult. This persistent
abnormality in medullary perfusion appears to be due to at least
two independent factors: intrarenal vasoconstriction, and the
physical congestion of the medullary vasculature by red cells,
platelets, and leukocytes. Let us look at the mechanisms under-
lying each of these factors separately.
Intrarenal vasoconstriction. Although renal tubular epithelial
cells are clearly the principal target of injury in ATN, injury to the
vascular endothelium contributes to the intrarenal vasoconstric-
tion associated with acute renal injury. Endothelial dysfunction
leads to an imbalance in endothelin (ET) and endothelium-
derived nitric oxide (EDNO) production in ATN.
The endothelins are a family of peptides of 21 amino acids
produced by the endothelium [191. The three isoforms of ET
(ETI, ET2, and ET3) all arc produced in renal tissue [19]. This
dicusssion will focus on the ETI isoform, the only one clearly
known to play a role in ARF [19]. Not only is it the most potent
vasoconstrictor yet described, ETI also has greater vasoconstrictor
activity in the renal vasculature than in any other vascular bed [19].
Also, ET1 has unusually long-lasting vasoconstrictor activity [19].
Understanding the mechanisms involved in the production and
action of ET provides many opportunities for therapeutic block-
ade of this system. The mature ET peptide is produced from its
precursor, prepro El', by a two-step process. Prcpro El' is first
converted to "big ET." Big ET, which has little vasoconstrictor
activity, is then converted to the mature (21 amino acid) ET by a
specific endopeptidase called endothelin-converting enzyme
(ECE) [19]. Two receptors for endothelin (ETA and ETB) reside
in the kidney [19]. The ETA receptor, present on vascular smooth
muscle, mediates most of the vasoconstrictor effects of ET1 (Fig.
1). The ETB receptor is expressed predominantly on endothelial
cells, where it stimulates the release of nitric oxide from endothe-
hal cells (Fig. 1) [10]. The ETB receptor generally has been
viewed as a mechanism for offsetting the vasoconstrictive effects of
ETI. However, the ETB receptor is also expressed to some extent
in some smooth muscle cells, where it can also mediate vasocon-
striction (Fig. 1) [19]. Thus, ET production and its resulting
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Fig. 1. The normal balance of endothelial
production of endothelin and nitric oxide
(EDNO) within the kidney (panel A) is reversed
following acute renal injury (panel B).
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vasoconstriction potentially can be blocked at multiple points,
including inhibition of ET1 gene transcription, blockade of the
conversion of prepro ET to big ET, inhibition of the ECE and,
finally, ET receptor blockade [19].
Endothelin-receptor blockers (either specific ETA receptor
antagonists or antagonists that block both ETA and ETB recep-
tors) improve renal function and ameliorate the morphologic
severity of tubular injuly associated with experimental ischemic
ARF [20—22]. Also, ET receptor antagonists reverse intrarenal
vasoconstriction and improve renal function following a number
of nephrotoxic insults that commonly cause ARF, including acute
cyclosporine administration [23, 24], rhabdomyolysis [25], and use
of radiocontrast medium [26]. In addition to ET receptor block-
ade, other potential therapeutic modalities inhibiting the ET
system in ARF include specific inhibitors of ET gene transcription
and ECE inhibitors. It is of interest that atrial natriuretic peptide
(ANP) inhibits transcription of the ETI gene and reduces synthe-
sis of the ETI peptide [27]. This effect might contribute to ANP's
well-documented protective effect in ischemic and toxic forms of
experimental ARF [1, 13].
How does endothelin produce such severe and long-lasting
vasoconstriction in ARF [28, 29]? Kon's group has demonstrated
that cyclosporine nephrotoxicity is associated with increases in
ET1 gene expression, ET peptide production, and expression of
the ETB receptor, all of which can persist for hours to days after
the insult [28]. The same group also has demonstrated that ETB
receptors on endothelial cells mediate the autoinduction for ETI
synthesis (Fig. 1) [29]. On the basis of these interesting findings,
Kon and associates have suggested that renal injuries associated
with ARF induce synthesis of endogenous ET1, which then
perpetuates its own production after the initiating injury has
resolved (Fig. 1) [28, 29].
Evidence suggests that sublethal endothelial injury, in addition
to increasing ET release, simultaneously reduces the release of
EDNO produced by the constitutive nitric oxide synthase (eNOS)
(Fig. 1) [1]. This reduction in EDNO production has been
described in response to many renal insults that result in ATN,
including ischemia [12, 30], cyclosporine toxicity [31], and pigment
(myoglobin and hemoglobin)-induced ARF [32]. Some evidence
indicates that renal cNOS activity recovers within 24 to 48 hours
after an ischemic insult [33], but the reduction in cNOS activity
and EDNO production following cyclosporine toxicity and pig-
ment-induced renal failure is more persistent (Fig. 1) [31, 34]. A
deficiency in NO production in ARF can contribute to vasocon-
striction in a number of ways. First, the constitutive production of
NO normally plays an important roic in regulating vascular tone
by maintaining basal systemic and renal arterial vasodilation [35].
Lack of EDNO also can be detrimental by increasing ET produc-
tion and vasoconstrictor activity; NO downregulates the produc-
tion and activity of endothelin in vitro both by inhibiting gene
transcription and production of ET [36], as well as by modulating
the effect of ET on its receptor (Fig. 1) [37]. We recently reported
the results of rat studies demonstrating the importance of EDNO
as an inhibitor of ET production in vivo [38].
Thus, many causes of experimental ARF, including ischemia,
hemoglobinuria, myoglobinuria, and cyclosporine, are associated
with the dual and additive effects of an increase in endothelin-
induced vasoconstriction and a reduction in EDNO-induced
vasodilation (Fig. 1). Radiocontrast medium is the only nephro-
toxin known to stimulate endothelial production of both endothe-
un [26] as well as endothelial vasodilators including prostaglan-
dins and EDNO [26, 391. Brezis and associates have suggested
that EDNO's response to radiocontrast medium is a protective
mechanism against radiocontrast-medium-induced production
of ET and that the predisposition of patients with underlying
chronic renal failure, diabetes, and vascular disease to radio-
contrast-medium-induced ARF [1] may be due to the presence
of chronic underlying endothelial injury, which blunts or pre-
vents EDNO release in response to the administration of this
nephrotoxin [15, 39].
Our understanding of the role of NO in ARF has been
expanded, and at the same time complicated, by recent studies
implicating NO produced by ischemic tubular cells as a mediator
of cellular injury [40, 41]. The NO produced by tubular cells is
generated by an inducible nitric oxide synthase (iNOS), an
enzyme distinct from cNOS. Ischemia increases the activity of
iNOS. The resultant increase in production of NO within the renal
tubular cells likely contributes to cytotoxicity, possibly by combin-
ing with superoxide to form the oxidant peroxinitrite [40, 41].
Sepsis also increases iNOS activity, and septic patients' predispo-
sition to ATN might be related in part to increased tubular
generation of NO [42].
In summary, in patients with ARF, opposing abnormalities in
NO production within the endothelial and tubular compartments
of the kidney contribute to renal injury. Reduced endothelium-
derived NO production causes vasoconstriction and worsens
ischemia; increased NO production by tubular cells exacerbates
the injurious effects of ischemia on these cells. This compartmen-
talization of NO likely explains why neither NO donors (such as
nitroprusside) [13] nor nonspecific NO inhibitors have a protec-
tive effect in ARF [41]. Any therapeutic intervention designed to
modulate NO in ARF requires selective alterations of NO pro-
duction within endothelium and/or renal tubular cells. Goligor-
sky's group has led the way in this challenging area by showing
that antiscnse oligonucleotides to iNOS both ameliorate injury of
renal cells in culture that have been exposed to oxidative stress
[41] and improve renal function in an isehemic model of ARF in
vivo [43].
Medullaty congestion. In addition to vasoconstriction, medullary
isehemia due to congestion and physical obstruction of the
capillaries of the outer medulla by red cells, platelets, and
leukocytes also contributes to the persistent reduction in medul-
lary perfusion associated with ARF [16, 17, 44—46]. Although
some investigators have stressed the importance of leukocytes in
contributing to medullary congestion [44, 46, 471, the role of
leukocytes in the pathogenesis of ARF has remained controversial
until recently [1, 4]. One of the many benefits of the explosion of
knowledge regarding the structure and function of leukocyte
adhesion molecules [481 has been the clear evidence that ischemic
injury to many organs, including the kidney, stimulates the release
of inflammatory mediators that in turn activate the adhesion
molecules on leukocytes and the expression of their ligands on
endothelia! cells [48]. These events lead to increased leukocyte-
endothelial adhesion and endothelial injury, analogous to the
events associated with a classic inflammatory reaction [48]. Anti-
bodies that neutralize the binding activity of either the adhesion
molecules on leukocytes [49] or on endothelial cells [50—52]
substantially ameliorate the functional and histologic injury asso-
ciated with ischemic ARF. The conclusions of these studies using
antibodies have been substantially strengthened by the finding
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Table 1. Potential responses of renal tubular cells to renal injury
Sublethal injury
Cellular dysfunction
Loss of polarity
Loss of tight junction gate function
Loss of cell-substrate adhesion
Exfoliation of viable cells from tubular basement membrane
Aberrant renal tubular cell-cell adhesion
Altered gene expression
Cellular dedifferentiation
Recovery of cell function
Lethal injury
Necrosis
Apoptosis
that knockout mice lacking the gene for ICAM-1, the endothelial
ligand for leukocyte adhesion molecules, also are protected
against acute ischemic renal injury [53].
The mechanisms by which leukocytes promote ischemic renal
injury remain incompletely defined, but considerable evidence
indicates that leukocytes contribute to the persistent hemody-
namic impairment associated with ischemic injury [531 both by
releasing vasoconstrictors (such as leukotrienes and thrombox-
ane) [47] as well as by causing endothelial injury, which leads to
the congestion of the capillaries of the outer medulla by red cells,
leukocytes, and platelets [16, 17, 44—46, 54]. Furthermore, the
imbalance I have described in endothelin and EDNO production
associated with renal injury likely contributes to the leukocyte-
induced damage. The constitutive release of EDNO into plasma
inhibits activation of leukocytes [55] while endothelin promotes
the adhesion of leukocytes to endothelial cells [54]. Thus, the
protective effects of endothelin blockade are likely due not only to
reduced endothelin-mediated vasoconstriction, but also to block-
ade of endothelin-induced leukocyte activation and amelioration
of medullary congestion [541.
Leukocyte-induced injury also probably contributes to the
exacerbation of acute renal damage in patients with established
ATN undergoing hemodialysis. "Incompatible" dialysis mem-
branes made of cellulose acetate activate leukocytes [56]. A
reduction in leukocyte-induced renal injury probably accounts for
the important observation by Hakim et al [57] that patients with
ARF are more likely to survive and recover renal function when
dialyzed with a relatively biocompatible dialysis membrane than
with a bioincompatible membrane. Thus, the development of
effective antibodies or soluble antagonists directed against the
panoply of adhesion molecules associated with leukocyte-induced
injury [481 may provide novel and potentially additive forms of
treatment to prevent or ameliorate ARF.
Ischemic and toxic injury to tubular cells
Although the term ATN accurately defines the population of
cells most severely injured in this disease, it fails to provide a sense
of the multiplicity of responses that renal tubular epithelial cells
demonstrate following an ischemic or toxic insult (Table 1).
"Acute tubular necrosis" implies that the predominant response
of tubular cells to injury is cell death by necrosis. Necrosis of some
tubular cells clearly occurs, but morphologic studies of ATN in
humans over the last 2 to 3 decades have revealed that areas of
frank necrosis are focal and relatively sparse [58, 59]. In fact, the
marked disparity between the relatively subtle histologic lesions
seen in biopsy specimens from humans with ATN and the
profound reduction in GFR characteristic of this disease is a
well-recognized paradox. One of the main themes of this Nephrol-
ogy Forum is that renal tubular cells can respond to renal injury
in many different ways (Table 1) [58, 59]. Many tubular segments,
including the distal convoluted tubule and collecting duct, prob-
ably escape injury altogether. Tubular cells that are lethally
injured can die by apoptosis, a process distinct from necrosis [601.
Finally, accumulating evidence suggests that many renal tubular
cells are sublethally injured and, while appearing intact morpho-
logically, can still contribute to the tubular leakiness and obstruc-
tion associated with ARF (Table 1) [61, 62].
Sublethal injury. Sublethal injury markedly impairs the function
of renal tubular cells. Injury to the cytoskeleton contributes to
many of these functional disturbances [61, 62]. The actin cytoskel-
eton plays an important role in epithelial cell function; this subject
is discussed in greater detail in two excellent reviews [63, 64].
Briefly, however, the actin cytoskeleton is important in many
aspects of normal cell function and structure, including mainte-
nance of normal brush-border structure, cell polarity, tight junc-
tion integrity [65] and normal adhesion of epithelial cells to the
tubular basement membrane of the nephron [63, 64]. The alter-
ations in the actin cytoskeleton that occur in the absence of
irreversible injury and cell death contribute importantly to cell
dysfunction by causing abnormalities in each of these cell func-
tions.
The actin cytoskeleton is present as a layer of microfilaments
below the apical plasma membrane, where it forms the terminal
web. Bundles of actin filaments extend from the terminal web into
the microvilli and contribute to the architectural stability of the
brush border [66]. Kellerman and Bogusky have reported that
ischemic injury to the kidney in vivo rapidly disrupts the actin
cytoskeleton of the microvilli and redistributes F-actin microfila-
ments from the microvilli into the cytosol [67]. These findings
provide an explanation at a molecular level for the disruption of
the proximal tubular brush border noted many years ago both in
experimental models of ischemic injury [6] as well as in humans
with ATN [58].
The important concept that sublethal injury to tubular cells is
associated with profound alterations in the function of the
nephron was initially suggested by Molitoris, who demonstrated
that sublethal injury leads to loss of the normal polarity of renal
epithelial cell monolayers [61, 65, 66, 68]. Loss of cell polarity
occurs when the "fence" function of the tight junction fails [63].
Molitoris and colleagues have shown that the Na/K-ATPase,
which is normally restricted to the basolateral cell membrane,
redistributes following sublethal injury and results in the presence
of functional Nat/K' -ATPase molecules on the apical domain of
the cell [61, 65, 66, 681. This event follows disruption of the actin
cytoskelelon, which normally "anchors" the Na /K -ATPasc
molecules to the basolateral cell membrane. Loss of polarity of
the Na/K -ATPase profoundly disturbs the normal unidirec-
tional transport of salt and water of the renal epithelial cell [61,
65, 66, 681.
Further investigation by Molitoris and other investigators has
added to our understanding of the ways in which sublethal injury
can alter the function of renal epithelial cells [62, 68—741. In
addition to its "fence" function, the tight junction also has a
"gate" function, which refers to the barrier to paracellular move-
ment of water and solute across all normal epithelia. The "gate"
function of renal tubular cells is also markedly impaired by
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sublethal injury [62, 68]. This loss of gate function prevents the
renal epithelium from acting as a barrier to free movement of
solute and water across the tubular epithelium. Thus, severe
"backleak" of glomerular filtrate can occur in the absence of lethal
injury and without any apparent morphologic evidence of tubular
cell injury [62]. The loss of both "fence" and "gate" functions of
the tight junction is reversible if the cell ATP content recovers
before lethal cell damage ensues [62].
in addition to loss of tight junction integrity, sublethally injured
renal cells undergo a loss of cell-matrix adhesion. Epithelial cells
are normally attached to the underlying matrix by the 131 integrin
family of transmembrane proteins normally localized to the basal
aspect of the cell. This protein has an intracellular domain that
connects to the actin cytoskeleton via a complex of proteins called
the adhesion plaque [64]. The extracellular domain of the protein
attaches to receptors present on matrix proteins, such as fibronec-
tin and collagen, which constitute the tubular basement mem-
brane [64]. One well-defined matrix receptor for the 131 integrin is
a tripeptide sequence of arginine-glycine-asparagine (abbreviated
as RGD) present on many matrix proteins. The loss of polarity
associated with sublethal injury to renal cells causes redistribution
of proteins other than the Na 7K-ATPase that include the /31
integrins. As a result, /3 iritegrins also become expressed on the
apical domain of sublethally injured renal cells (Fig. 2) [69, 70].
The redistribution of the /31 integrin probably explains, at least in
part, the observed impairment of cell-substrate adhesion in sub-
lethally injured renal cells in culture [62, 69, 71, 72].
The disruption of cell-substratum attachment demonstrated in
vitro following sublethal injury is relevant to the pathophysiology
of human ATN. Detachment of renal epithelial cells from base-
ment membrane has been documented by morphologic studies of
renal biopsy specimens taken from humans with ATN [59]. Acute
renal failure also is associated with the loss of viable tubular cells
from the nephron and their excretion in the urine [59]. Thus, in
addition to lethal cell injury and loss of tight junction function, the
detachment of viable cells from the renal epithelium provides yet
another mechanism for backleak of glomerular filtrate.
Goligorsky and associates have expanded our understanding of
the likely functional consequences of sublethal injury to renal
tubular cells by hypothesizing that sublethal injury leads to
intratubular obstruction as well as to backleak of glomerular
filtrate [70]. They hypothesized that loss of f31 integrin polarity
leads to aberrant binding of tubular cells to one another so that
exfoliated tubular cells attach to one another as well as to
non-exfoliated, sublethally injured cells (Fig. 2) within the tubular
lumen [70, 71]. The hypothesis, described schematically in Figure
2, is based on data from renal cells in culture, which suggest that
the /31 intcgrins expressed on the surface of sublethally injured
cells remain functionally capable of binding to their RGD recep-
tor [69, 70, 72]. On the basis of this hypothesis, Goligorsky's group
theorized further that administration of an excess of soluble
RGD-containing molecules would saturate the extracellular bind-
ing site of all exposed 131 integrins within the lumen of the
nephron and thus prevent or ameliorate renal tubular cell-cell
adhesion and intratubular obstruction (Fig. 2) [71]. To test this
hypothesis in vivo, they examined the effect of an intravenous
infusion of soluble, RGD-containing peptides into rats with
established ischemic ARF and found that the RGD-containing
peptides ameliorated the reduction in GFR associated with
ischemic injury [71, 73]. While RGD-containing peptides can have
Normal renal epithelium
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Fig. 2. Sublethal injury to renal tubular cells leads to exfoliation of
viable renal tubular cells and aberrant 1 integrin-mediated cell-cell
adhesion. (Adapted from Ref. 71 with permission.)
other, as-yet-unidentified mechanisms of action in ARF, this
beneficial effect is probably mediated, at least in part, by prevent-
ing intratubular obstruction (Fig. 2) [74].
Further studies are needed to clarify the mechanisms by which
RGD mediates its protective effect. Also, the possibility that
adhesion molecules other than the /31 integrin (such as clusterin
or cadherin, which mediate cell-cell adhesion) or matrix receptors
other than RGD contribute to the pathogenesis of ARF needs to
be investigated. The therapeutic potential of multiple soluble
factors that interfere with tubular cast formation by binding to
adhesion molecules and/or to their matrix receptors remains an
exciting area of basic investigation.
Lethal cell injury: Necrosis. The morphology and biology of
necrosis of tubular cells following injury have been discussed in
detail elsewhere [4, 75]. 1 will discuss necrosis only briefly in this
Nephrology Forum to emphasize the important differences he-
twecn necrosis and apoptosis. Cell necrosis is induced by rapid
and overwhelming depletion of cellular energy stores and by
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irreversible injury to the lipid bilayer of the plasma membrane and
subcellular organelles [4, 75, 761. These events disrupt membrane
integrity and transport activity and induce cell swelling as a result
of the entry of sodium and water into the dying cell [4, 75]. Loss
of plasma membrane integrity later allows cytosolic contents
containing proteolytic enzymes to leak into the extracellular
space. The resultant injury to and inflammation of surrounding
tissues is easily observed histologically.
In necrotic cell death, many derangements in cellular metabo-
lism occur concurrently and in an uncoordinated but additive
manner. These alterations ultimately cause the rapid demise of
the cell. Some of the biochemical events that are the putative
causes of necrosis are listed in Table 2 [4, 75]. Because the events
that lead to necrosis are chaotic and unregulated and involve
multiple and diverse metabolic pathways, attempts at developing
therapeutic strategies to prevent necrosis after an ischemic or
toxic event have been only partially effective at best.
Apoptosis. In direct contrast to necrosis, apoptosis is a carefully
choreographed and genetically directed form of cell death that
requires energy [60, 76]. The morphologic characteristics of
apoptosis and necrosis are quite distinct and remarkably constant
among different cell types [76, 77]. In contrast to necrosis, cells
dying by apoptosis become progressively smaller as cytosolic
volume decreases and the nucleus condenses [771. This process
can be identified by light or fluorescent microscopy with the
appropriate staining techniques: the normal chromatin structure
of the nucleus is lost and the nucleus appears as a round,
featureless mass [60, 78]. The most reliable way to recognize
apoptosis is by transmission electron microscopy, in which the
intact plasma membrane and subcellular organelles as well as
nuclear condensation are specific features [77].
Another feature unique to apoptosis is the fragmentation of the
condensed nuclei into multiple pieces. The apoptotic cell eventu-
ally breaks apart into many "apoptotic bodies," pieces of nuclear
material surrounded by a rim of cytoplasm and enclosed by an
intact plasma membrane [77, 781. Apoptotic cells and bodies are
phagocytosed by resident macrophages, as well as by surrounding
epithelial cells and fibrohiasts. This clearance mechanism is
extremely efficient, and apoptotic cells and bodies disappear
rapidly from the tissue without any trace of surrounding tissue
injury or inflammation. For this reason, apoptosis is usually
inconspicuous and difficult to detect in tissue sections, even when
responsible for extensive cell loss [60, 71.
Many factors can cause apoptosis (Table 3). Jerrold Levine and
I have reviewed these factors in a recent review article [60]. The
realization that both apoptosis and necrosis can be induced by the
same noxious stimuli has resulted in much interest in the role of
apoptosis in different forms of renal injury, including ATN [60].
Apoptosis is a common response in cells exposed to modest
Table 3. Potential causes of apoptosis of renal tubular cells in ARF
Physiologic activators
TNFa
TGF
Loss of "survival" factors
Deficiency of renal growth factors
Impaired cell-matrix adhesion
Loss of cell-cell adhesion
Cytotoxic agents
Hypoxia; ischemia; anoxia
Reactive oxygen species
Increased intracellular free calcium
Hyperthermia
Nutrient deprivation
Irradiation
Pharmacologic agents
Chemotherapeutic agents
Cyclosporine; rapamycin
Irradiation
ischemia or to toxins at concentrations below those required to
induce rapid metabolic collapse and necrosis [60, 79]. It seems as
if lethally injured cells not rapidly killed by necrosis detect the
injurious signal and initiate the apoptotic pathway. We have
demonstrated that cisplatin, a common cause of ATN, induces
necrosis of renal tubular cells in culture when these cells are
exposed to high concentrations (--l mm) of the drug. In contrast,
much lower concentrations (—50 /.tm) of cisplatin produce the
classic morphologic features of apoptotic cell death [781. Our
study confirms the observation made by others in many different
cell types that the mechanism of renal tubular cell death depends
on the severity of the injury [79].
Other known triggers of apoptosis might be important in ARF.
One important cause of apoptosis is a relative deficiency of
essential "survival factors" that are necessary not only for cell
growth, but also for the maintenance of cell viability [80]. The
apoptotic program therefore can be regarded as a "default
pathway," which is always ready to be activated unless it is
constantly suppressed by survival factors. Survival factors include
soluble growth factors as well as signals transmitted into the cell
from interactions between cells (cell-cell adhesion) or between
cells and their underlying matrix (cell-substrate adhesion) [80].
Epithelial cells depend on normal cell-cell and cell-matrix
adherence to remain viable. Loss of signals received from these
normal interactions also leads to apoptosis. Thus the loss of
normal cell-cell and cell-matrix adhesion associated with cell
injury [621 might lead to apoptosis in ARF. The soluble growth
factors necessary for survival depend on the cell type. Renal
tubular epithelial cells in culture die by apoptosis in the absence
of renotrophic hormones such as epidermal growth factor (EGF)
and insulin-like growth factor-i (IGF-1) [81]. Perhaps the defi-
ciency of renal EGF production that occurs following acute renal
injury [82, 83] contributes to tubular cell apoptosis in ARF.
Another inducer of apoptosis in epithelial cells, TNFa, might
contribute to ARF in septic states associated with an increased
production of this cytokine [60].
The complex mechanisms involved in what has become known
as the "execution" phase of apoptosis are still unfolding. One of
the most intruiging enigmas in the cellular biology of apoptosis is
how such a bewildering diversity of precipitating factors can result
in a genetically controlled form of cell death with the same
Table 2. Mechanisms of cell necrosis
Severe depletion of cellular ATP stores
Redsiced activity of membrane transport pumps
Cell swelling
Increase in intracellular free calcium
Activation of phospholipases
Activation of proteases
Glycine depletion
Plasma and subcellular membrane injury
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morphologic manifestations. One biochemical event characteristic
of apoptosis is the activation of an endonuclease that causes
fragmentation of DNA [76]. In apoptosis, the endonuclease acts
at internucleosomal sites, generating fragments of DNA in integer
multiples of nucleosomal size (200 base pairs). This fragmentation
produces the "ladder" pattern seen when DNA from apoptotic
cells is subjected to agarose electrophoresis. In contrast, during
necrosis, DNA typically is degraded into small fragments of
varying lengths, resulting in a "smear" pattern on DNA electro-
phoresis [60]. Another convenient method for identifying in intact
cells or tissue sections the DNA fragmentation associated with
apoptosis is by end-labeling the free ends of the DNA generated
by endonuclease activity with a fluorescently labeled nucleotide
via the enzyme terminal deoxynucleotidyl transferase (TUNEL)
method [84]. A ladder pattern on DNA electrophoresis and/or
positive TUNEL staining strongly supports apoptosis. However,
one must recognize that the ladder pattern of DNA fragmentation
is not completely reliable for distinguishing apoptotic from ne-
crotic cell death. Apoptosis, defined morphologically, can occur in
the absence of internucleosomal DNA cleavage, and DNA lad-
dering or positive TUNEL staining has been demonstrated in
renal epithelial cells that undergo necrosis in response to hypoxia-
reoxygenation injury [60, 85]. Thus, the biochemical feature of
endonuclease activation, although characteristic of most cells
undergoing apoptosis, has been dissociated in some situations
from the classic morphologic changes that define apoptotic cell
death [60, 77]. Furthermore, the importance of endonuclease
activation as an initiating event in the execution phase of apopto-
sis has been questioned [78].
ytoplasmic rather than nuclear events (such as endonuclease
activation) probably play the initiating and primary role in medi-
ating apoptotic cell death [86, 87]. A more proximal (upstream)
event in the execution phase of apoptosis involves the activation
of a cascade of proteases (Fig. 3) [86, 87]. A growing number of
studies support a role for members of the interleukin-1 convert-
ing enzyme (ICE) family of proteases in mediating apoptosis. All
members of the ICE-related family cleave substrates after an
aspartate residue. These enzymes are produced as inactive pro-
enzymes that are activated by cleavage at critical aspartate
residues that themselves conform to the substrate consensus for
ICE family proteases [86, 87]. It is currently believed that one or
a few ICE-like proteases are initially activated following an
apoptotic "trigger." These proteases then activate additional
ICE-like protcases in successive and expanding hierarchies (Fig.
3) [86, 87]. This proteolytic cascade ultimately leads to the
activation of proteascs that target multiple proteins within the
cells. The proteolytic cleavage of these cytoplasmic and nuclear
substrates leads to the demise of the cell by apoptosis (Fig. 3) [86,
87].
Nuclear substrates of ICE-like proteases known to be cleaved in
apoptosis include the DNA repair enzyme poly(ADP-rihose)
polymerase (PARP) and lamin, the nuclear envelope protein
lamin [87]. Cleavage of lamin might contribute to the nuclear
condensation and fragmentation characteristic of apoptosis [87,
881. Protease activation of endonucleases also might lead to the
DNA fragmentation associatcd with apoptosis [87]. ytoplasmic
substrates for ICE-like proteases also include cytoskeletal pro-
teins such as actin and fodrin [86, 87, 89]. The extent to which
cleavage of cytoskeletal proteins induces the phenotypic changes
of apoptosis (such as cell membrane "budding") is unknown. The
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Fig. 3. The execution phase of apoptosis is mediated by activation of an
ICE-like protease, which leads in turn to activation of a cascade of related
proteases that ultimately cleave multiple cytoplasmic and nuclear sub-
strates.
recent description of inhibitors of ICE-like proteases that can
prevent apoptosis induced by a number of stimuli has reinforced
the concept that activation of proteases is a proximal and impor-
tant event in apoptosis (Fig. 3) [90, 91]. These studies also suggest
that the development of inhibitors of apoptosis have therapeutic
potential in conditions such as ARF in which apoptosis contrib-
utes to loss of renal tubular epithelial cells.
The Bcl-2 family of proteins is important in regulating the
execution phase of apoptosis [92]. The Bcl-2 protein as well as
other members of this family (such as BAG-i and Bcl-XL) protect
cells against apoptosis. In contrast, other Bcl-2-like proteins (such
as Bad, Bak, and Bcl-X) promote cell death. Thus, for any given
apoptotic stimulus, the balance between death and survival ap-
pears to be determined by the ratio of apoptosis-promoting and
-suppressing Bcl-2 family proteins [92]. Although the mechanism
by which members of the Bcl-2 family regulate apoptosis is not
known, it is clear that the susceptibility of cells to apoptosis can be
altered by changing the level of expression of individual family
member proteins. Alteration in the expression of various mem-
bers of the Bcl-2 family of proteins provides another therapeutic
strategy by which cells can be pharmacologically manipulated to
either prevent or facilitate apoptosis.
Despite the difficulty in identifying apoptotic cell death in tissue
sections, evidence has emerged suggesting that apoptosis contrib-
utes to cell death following ischemia and/or reperfusion injury in
vivo in the kidney [93, 94] as well as in other organs such as the
heart [95]. However, this area remains controversial because sonic
investigators have been unable to demonstrate any morphologic
Morphologic and biochemical features of apoptosis
• Nucleosomal DNA cleavage
• Nuclear condensation
• Nuclear fragmentation
• Cytoskeletal changes
• Cell membrane budding
• Apoptotic bodies
• PHAGOCYTOSIS
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evidence of apoptosis following ischemia and/or reperfusion in-
jury to kidneys in vivo [96]. We have examined the mechanisms of
cell death in proximal tubular cells in culture and have demon-
strated apoptosis in response to multiple stimuli, including renal
growth factor withdrawal [811, chemical anoxia [97], and cytotoxic
agents such as cisplatin [78]. Clearly, in view of the potential for
pharmacologic interventions that could inhibit apoptosis, studies
to establish the mechanisms of apoptosis in renal tubular cells and
the extent to which apoptosis contributes to the loss of these cells
following ischemic and toxic renal injury have become extremely
important.
Recovery from ATN
A striking characteristic of ischemic and toxic ATN is that the
injured and dysfunctional kidneys usually recover normal struc-
ture and function. This dramatic process depends on a complex
series of events, including recovery of sublethally injured cells as
well as the removal of intratubular cellular debris and casts.
Finally, an essential part of the recovery process is replacement of
tubular cells that are lost via exfoliation of viable cells from the
tubular epithelium or by cell death from necrosis or apoptosis.
This process requires replication of surviving, viable renal cells in
areas of cell loss [82].
Under normal circumstances, renal tubular cells in vivo are
quiescent and do not readily divide in response to growth factors.
However, following an ischemic or nephrotoxic insult, surviving
renal tubular cells re-enter the cell cycle and replicate, thus
replacing irreversibly injured cells [14, 82]. These cells possibly
undergo partial dedifferentiation that allows them to undergo
mitosis (Table 1) [14, 82]. The complex series of events that
mediate this process is still being elucidated. What is known is that
cell regeneration begins very soon after the noxious insult [82].
Ischemic and nephrotoxic renal injury both induce alterations in
gene expression similar to those induced by growth factors in cells
in culture [82]. Transient expression of genes such as c-fos and
egr-1 [14, 981, as well as KC and JE [99], occurs almost immedi-
ately after renal ischemia and precedes increased protein or DNA
synthesis. Some of these genes (such as the "early immediate
response genes" egr-1 and c-fos) code for DNA-binding transcrip-
tion factors that likely initiate the transcription of the many other
genes necessary for cellular division [14, 82]. Other genes such as
KG and JE code for proteins with chemotactic effects that can
attract into areas of injury monocytes and other neutrophils that
participate in the reparative response [82].
It is interesting that most studies have localized the expression
of these genes to the mTAL segment of the nephron; other
nephron segments show little evidence of altered gene expression
[14, 99, 100]. A complex system of biochemical pathways must
remain intact for mTAL cells to perceive an injurious stimulus
and to modulate transcription of the appropriate genes in re-
sponse to this "stress" signal [82, 100]. For these reasons, the
studies demonstrating activation of gene expression in mTAL
cells add to the evidence that I summarized earlier that argues
against the mTAL segment being a major site of lethal cell injury
in ARF [1, 6, 10, 11]. Furthermore, the close anatomic proximity
of the S3 segments of the proximal tubule and mTAL segments
within the outer medulla suggests the intriguing possibility that
growth factors and cytokines released by mTAL cells following
renal injury act in a paracrine fashion to stimulate the regenera-
tion of neighboring cells in the S3 segment of the proximal tubule,
where irreversible cell injury has occurred [82].
The molecules that mediate the proliferative response after
renal injury have not been defined, and the role of known
proximal tubular cell mitogens—such as EGF, IGF-1, transforming
growth factor (TGF-a), and hepatocyte growth factor (HGF)—
remains uncertain [98]. Further clarification of the responses to
sublethal injury at a genetic level may ultimately provide the tools
to alter this response in ways that accelerate repair and regener-
ation in patients with ATN. This line of research has stimulated
investigation of a number of renotrophic hormones as therapy of
ARF. I will conclude by briefly reviewing this issue.
Renal growth factors, including EGF [101], IGF-1 [102], and
HGF [103], already have proved effective in facilitating recovery
of renal function in experimental animals when administered after
an ischemic or toxic insult to the kidney [104]. The mechanisms
responsible for this beneficial effect are still being actively inves-
tigated, but it is known that these growth factors stimulate
regeneration of cells following injury; EGF, IGF, and HGF are all
known mitogens for proximal tubular cells [104]. Also, the expres-
sion of the receptors for renal cell growth factors is increased after
acute renal injury in rats [104]. These observations explain the
robust proliferative response of tubular cells following adminis-
tration of these mitogens after injury.
Growth factors also might inhibit apoptosis in ARF [60]. As I
have already mentioned, there may be a relative deficiency of
renal growth factors such as EGF in ARF [83]. The administration
of growth factors might inhibit apoptosis by replacing necessary
survival factors that inhibit activation of the "default" pathway of
apoptosis. While theoretically feasible, the extent to which admin-
istration of growth factors promotes recovery of ARF by inhibit-
ing apoptosis remains to be established.
To summarize, I have emphasized in my discussion how basic
research, by elucidating the molecular and cellular events respon-
sible for ARF, has led to the promise of new therapies for this
common disease. The next few years should prove an exciting time
for clinical researchers interested in examining the efficacy of
these agents, either alone or in various combinations, in their
patients with ATN.
QUESTIONS AND ANSWERS
DR. NIcoLAos E. MADIAS (Chief Division of Nephrology, New
England Medical Center, Boston, Massachusetis): You have dis-
cussed a long list of contributory factors in the pathogenesis of
acute renal failure and suggested a number of strategies for
intervention. In your judgment, which avenues would be the most
rewarding to pursue for further research in terms of prevention
and amelioration of established acute renal failure?
DR. LIEHFRTHAI.: The route taken in clinical studies to examine
the efficacy of various experimental agents shown to ameliorate
ARF in animals will largely be determined by the process of FDA
approval. Two of the agents mentioned in my discussion, atrial
natriuretic peptide (ANP) and the growth factor IGF-1, already
are being examined in humans with ATN. Antibodies to some of
the leukocyte adhesion molecules have been tested in phase-I
human trials and will soon be available for studies in ARF. The
testing of these antibodies will be complicated by the large variety
of adhesion molecules involved in the process of leukocyte
adhesion and activation as well as by the experimental data
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suggesting that blockade of some adhesion molecules (for exam-
ple, ICAM) is more effective than inhibition of others (such as the
selectins). Also, agents that block either the production of endo-
thelin (ECE inhibitors) or endothelin action (ET receptor antag-
onists) will be available soon for experimental use in humans.
Ultimately, combinations of these agents might be the most
effective form of treatment in ARF. The other strategies I
mentioned (such as disintegrins and ICE-like protease inhibitors)
are still in the early phase of experimental investigation.
DR. MADIAS: That leads me to my second question. Could you
tell us a bit about the experience with growth factors in animals
and, possibly, in humans with acute renal failure? Also, what are
the systemic effects of these compounds, and what is their impact
on the body's protein metabolism in acute renal failure?
DR. LIEBERTIIAI: A potentially important systemic consequence
of IGF-1 administration is its potent anabolic effect, which has
been well documented in humans as well as in animals without
acute renal failure [102, 104]. The net catabolic rate is often
markedly elevated in acute renal failure, a metabolic complication
that can profoundly increase nutritional and dialysis require-
ments, impair wound healing, and increase overall morbidity and
mortality rates in patients with ATN [1]. Studies in animals have
demonstrated that IGF-1 reduces the rate of protein degradation,
stimulates protein synthesis, and substantially ameliorates the
marked loss of body weight associated with acute renal failure
[102, 104]. The improved metabolic milieu resulting from the
relatively greater GFR in IGF-1-treated animals probably con-
tributes to the associated reduction in catabolic rate. However,
IGF-1 appears to have anabolic effects that are independent of the
uremic state [1021. Furthermore, other growth factors such as
EGF do not appear to have effects on catabolic rate and body
weight in animals with acute renal failure equivalent to those of
IGF-1 [1041. Thus, it is possible that IGF-1 will turn out to be
particularly useful in the treatment of humans with ATN by
reducing protein breakdown as well as facilitating recovery from
renal injury.
DR. JOHN T. HARRINGTON (Dean, Tufts University School of
Medicine, Boston, Massachusetts): You said that backleak was one
of the mechanisms that underlie acute tubular necrosis. What's
the best evidence in humans for the existence of that phenome-
non?
DR. LIEBERTFIAL: The most convincing evidence that backleak
of glomerular filtrate plays an important role in the pathophysi-
ology of ATN in humans has been provided by Myers and Moran
[5]. They compared inulin clearance with the clearance of a
neutral dextran molecule, which is also freely filtered at the
glomerulus but is of larger molecular weight than inulin. Neither
molecule is reabsorbed or secreted by the renal tubules, so the
clearances of these two molecules by the normal kidney are
comparable (that is, fractional excretion of the dextran equals
unity). In contrast, in patients with ischemic ATN, dextran
clearance is substantially higher than that of inulin (fractional
excretion of the dextran exceeds unity). This indicates that inulin,
because of its smaller size, is able to passively "backleak" from the
tubular fluid at a faster rate than the dextran.
DR. HARRINGTON: You discussed the Epstein model of acute
tubular necrosis, in which an absence of red cells in the perfusate
causes necrosis in the medullary thick ascending limb. I had
assumed that this model was a well-oxygenated model. If that is
the case, why would the absence of red cells he so critical?
DR. LIEBERTHAL: The red-cell-free kidney represents a very
poorly oxygenated model. Whereas the cell-free perfusate has a
very high oxygen tension, the total oxygen content, which is
dependent on the oxygen dissolved in the aqueous phase, is very
low [8—111. In addition, loss of oxygen from the medulla by
countercurrent diffusion of oxygen is substantially exacerbated by
the lack of red cells [8—11]. Futhermore, in the uninjured isolated
perfused kidney, glomerular filtration is preserved, so the delivery
of solute to the tubules remains substantial. It is this unusual
combination of extremely poor oxygen delivery to the medulla
with the continuing high energy demands for sodium transport
that explains the susceptibility of the mTAL segments to necrosis
in this model [8—li]. This situation is unlikely ever to occur in
ATN in vivo because, by definition, GFR is severely reduced in
this situation and red cells are always present [9—il].
DR. RONALD PERRONE (Division of Alephrology, New England
Medical Center): You described an impressive array of experimen-
tal data derived primarily from rat models and cell culture. Are
there areas of human renal function or physiology, biochemistry,
etc., in which clear differences exist that we might want to target
differently? Do we know enough about all the pathways involved
to be able to extrapolate data from rats to humans?
DR. LIEBERTHAL: As you imply, experimental studies suggest
that the different processes that play a role in renal failure
(hemodynamic factors, tubular obstruction, tubular backleak)
contribute to a loss of GFR to varying extents in different models
of ARF. However, we know little about the relative role played by
these different pathophysiologic factors in humans with ATN.
Thus we are as yet unable to target different therapies for patients
with different causes of ARF.
DR. MADIAS: You didn't mention the renin-angiotensin system
in your talk, yet this system is activated in human and experimen-
tal acute renal failure, and angiotensin II has direct effects on
renal cells. Could you briefly discuss the role of the renin-
angiotensin system in the pathophysiology of acute renal failure,
even if to exclude it?
DR. LIEBERTHAL: That is an important question. For lack of
time, I have not discussed the potential role of the renin-
angiotensin system in ARF, but the vast body of literature on this
subject has been carefully reviewed elsewhere [1051. It is clear that
renin production by the kidney is increased in experimental
models of ARF. However, studies that have examined the effects
of either angiotensin-converting-enzyme inhibitors or angiotensin
IT-receptor blockade have produced variable results, with amelio-
ration of ARF in a few studies and no beneficial effect reported in
many others [105]. The role of the renin-angiotensin system in
humans is also unresolved [105]. It remains possible that in-
creased release of angiotensin II, most likely in a paracrine or
autocrine fashion within the juxtaglomerular apparatus, contrib-
utes to renal failure by inducing afferent arteriolar and/or mesan-
gial cell constriction [1, 4, 5, 105].
DR. ANDREW J. KING (Division of Nephrolo, New England
Medical Center): I am impressed with the animal data suggesting
that endothelin production increases following challenge with
cyclosporine or endotoxins and in the setting of acute tubular
necrosis [23—26, 106]. The data in humans are relatively sparse.
My recollection is that plasma endothelin levels are unchanged or
mildly elevated in patients with acute renal failure. Could you cite
any other evidence in humans that endothelin plays a role in the
pathogenesis of ATN?
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DR. LIEBERTHAL: I agree with your point that plasma endothelin
levels do not reflect the importance of endothelin in the patho-
physiology of ARF. However, it is important to appreciate that
endothelin is a paracrine hormone secreted to a large extent
through the basolateral aspect of endothelial cells and therefore
in the direction of vascular smooth muscle cells rather than the
plasma. For this reason, plasma levels are a relatively insensitive
marker of endothelin's contribution to any disease process. Futh-
ermore, if the abnormality of endothelin secretion is localized to
the vascular bed of one organ (for example, the kidney in ARF),
any increase in plasma endothelin levels from that organ will be
diluted in a peripheral plasma sample. Peripheral plasma endo-
thelin levels likely are increased only when the abnormality in
endothelin production is severe and present in multiple vascular
beds. This might explain the very high plasma levels of endothelin
in some patients, for example, those with hepatorenal syndrome.
To come back to your question, direct evidence for an involve-
ment of endothelin in disease in humans will have to await the use
of endothelin antagonists in clinical studies.
DR. KING: Would you please comment on the possible role of a
disturbance in tubuloglomerular feedback due to impaired nitric
oxide production in the pathogenesis of renal vasoconstriction in
patients with ATN?
DR. LIEBERTRAL: Nitric oxide, produced within the macula
densa by the neural NO synthase (nNOS), plays a role in
modulating afferent arteriolar tone and intraglomerular pressure
via the tubuloglomerular feedback mechanism. No studies have
directly examined the role of NO production at this site in ARF,
however.
DR. MknIAs: Would you comment on the following two inter-
ventional modalities used in acute renal failure? As you know,
"low-dose" dopamine infusion is used extensively without much
evidence of benefit but with considerable concern about the
associated risks. Also, calcium-channel blockers have been re-
ported to exert protective effects in experimental and clinical
acute renal failure.
DR. LIEBERTHAL: I agree entirely with your remarks regarding
dopamine. There is no evidence that it improves GFR, and there
is some concern that it is deleterious to critically ill patients. I
therefore do not recommend the use of dopamine for patients
with ATN. An excellent review on this subject was recently
published [107].
In response to the second part of your question on calcium-
channel blockers (CCB5), substantial experimental data indicate
that these drugs have potential as therapeutic agents in the
prevention and treatment of ARF. Also, a few convincing studies
in patients receiving cadaveric renal transplants suggest that CCBs
administered prophylactically (before and after transplantation)
are helpful in preventing or ameliorating ischemic ATN immedi-
ately following transplantation. I believe that additional con-
trolled human studies examining the efficacy of CCBs in the
prevention and treatment of ATN in other situations are still
warranted.
DR. MARK E. WILLIAMs (Renal Unit, Joslin Diabetes Center,
Boston): You mentioned that diabetes and pre-existing renal
impairment are risk factors for radiocontrast-medium-induced
ARF [1]. Also, you cited evidence that a dysfunctional renal
vascular endothelium might be responsible for the increased risk
of ARF in diabetic patients [39]. What factors might be respon-
sible for such susceptibility in chronic renal insufficiency? Why do
diabetic patients with normal renal function have basically similar
risk for acute renal failure as do non-diabetics?
DR. LIEnERTHAL: There are no definitive answers to your
questions. The pathophysiology of radiocontrast nephropathy is
complex and likely involves many interacting factors. In my
discussion I mentioned the animal studies [39] that have led to the
hypothesis that the susceptibility of patients with CRF to radio-
contrast nephropathy is due, in part, to dysfunction of endothelial
cells within the renal vasculature, which accentuates the renovas-
cular imbalance of endothelin and NO in these patients. Patients
with normal renal function, including diabetics, are more likely to
have relatively normal renovascular endothelial function.
DR. HARRINGTON: Let me ask a broader question. What differ-
ence does this all make? We all know that for the most part
patients don't die of acute renal failure; they die of sepsis or their
original disease. It seems to me that the same percentage of
patients, approximately two-thirds, die now following an episode
of ARF as did 20 years ago. How do we affect that larger issue?
DR. LIEnERTHAL: In my opinion, I feel your question reflects an
overly pessimistic view. I agree that there is a category of patients
with ARF who are so debilitated by age, immune deficiency,
and/or multi-organ failure that their survival is unlikely to be
altered by any intervention that ameliorates the concurrent pres-
ence of ARF. However, I also believe that for many patients, any
intervention that either prevents ARF or shortens the mainte-
nance phase of established ARF is likely to improve morbidity
and reduce mortality. The beneficial effect of the use of more
biocompatible dialysis membranes on the survival of patients with
ATN receiving hemodialysis [57] is just one indication that
patients with ATN are likely to benefit from any intervention that
reduces the need for dialysis altogether.
DR. MADIA5: Do growth factors influence the cytoskeletal
abnormalities of cells that have sustained sublethal injury?
DR. LIEnERTHAL: Yes. Substantial evidence has shown that
growth factors play a central role in initiating and modulating the
cytoskeletal events associated with the proliferative response. It is
quite feasible that the effect of growth factors in ARF is mediated,
at least in part, by promoting repair of the cytoskeleton.
DR. MAmAs: Did you say that apoptosis-related genes are
upregulated in models of acute renal failure?
DR. LIEnERTHAL: I know of no direct evidence as yet that
expression of genes related to the apoptotic process (such as genes
coding for the BCL2- or ICE-like protease families of proteins) is
altered in acute renal failure. However, as I discussed in some
detail, the expression of genes involved in the proliferative and
regenerative phase of ATN is upregulated following an ischemic
insult to the kidney.
DR. KING: An injured kidney loses its ability to regulate renal
blood flow. You raised the possibility that hemodialysis adds insult
to injury. Should we be taking any special approach to hemodial-
ysis for patients with ATN? For instance, should we delay it?
DR. LIEBERTHAL: The notion that repeated episodes of hypo-
tension during hemodialysis exacerbate ARF by causing repeated
acute ischemic injury remains an unproven hypothesis that is
based on two indirect sources. First, Conger demonstrated that
the renal autoregulatory response is impaired in rats with exper-
imental ARF [30] and has suggested, on the basis of these
findings, that the acutely injured kidney is more susceptible than
the normal kidney to repeated episodes of acute ischemic damage
during hypotensive episodes. Also, Solez reported that renal
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tissue from patients with ATN showing areas of regeneration
together with fresh lesions of acute ischeniia suggests that persis-
tent renal failure in ATN is associated with repeated episodes of
renal ischemia [58]. However, in answer to your question, I do not
believe that we should delay dialysis, when indicated, in patients
with ARF. The important question that remains to be answered
by the appropriate clinical studies is whether continous veno-
venous hemodialysis or other slow continuous therapies will prove
superior to conventional hemodialysis in treating patients with
ARF.
Reprint requests to Dr. W. Lieberthal, Renal Section, Boston Medical
Center, 88 East Newton Street, Boston, Massachusetts 02118, USA
NOTE ADDED IN PROOF
The proteins belonging to the ICE-like family of proteases have recently
been named "caspases" [1081.
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